Re: Percutaneous hepatic perfusion with melphalan in treating unresectable liver metastases of colorectal cancer and uveal melanoma: a phase I/II trial
And this is what I like: "On CT scans 5 weeks after the first treatment all target lesions decreased in size and were more hypodense. No new lesions were found in the liver. "
It works. It has always worked.
And mean hospital stay of 2.6 days - this is very good and much lower than it was in the beginning of PHP.
Now will Delcath survive long enough to prove scientifically that it works? Based on the numbers at the cc call today there is more than enough to make it through to the phase 2 results if they keep their timetable. With good phase 2 then a partnership or other capital source ( something I hope better than the darn ATM) would hopefully materialize.
Still, Delcath has a long long road ahead.